Definitive Contract 75N91021C00016
Award Date
9/13/21
Potential Completion Date
6/12/22
Potential Value
$393K
Federal Agency
National Cancer Institute
Awardee
Celartia, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Columbus, OH 43229, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This SBIR Phase I contract was awarded by the National Institutes of Health's National Cancer Institute to Cellfe Inc. for $358,930. The contract is for the period of September 8, 2020 through June 7, 2021 and involves research and development of a microfluidic transfection platform for rapid manufacturing of mRNA CAR lymphocyte products. The solicitation sought proposals to conduct R&D in support of NIH and CDC agency missions, including alternatives to cell culture materials and cancer...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Micromics Technologies LLC for the development of an "Integrated Platform for In-Depth Single-Cell Proteomics". The contract has a performance period from September 13, 2021 to June 12, 2022 and a ceiling value of $455,000. It is a firm fixed-price definitive contract set aside for small businesses. The original...
This Small Business Innovation Research (SBIR) Phase I contract, valued at $399,674, was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Inso Biosciences Inc., a small biotechnology startup. The contract supports the research and development of advanced sample processing platforms for downstream single-cell multi-omic analysis. This work aligns with the NIH and Centers for Disease Control and Prevention (CDC) mission to develop medical...
This is a $2,049,979.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Proteios Technology, Inc., a self-certified small disadvantaged business. The contract is for the development of a new paradigm for autologous and allogeneic cell therapy manufacturing, based on a previous SBIR Phase I award of $455,000 to the company. This contract was set aside for total small business...
The U.S. National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Celldex Therapeutics, Inc. in the amount of $199,398.00 on September 20, 2012. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type. The contract has an ultimate completion date of August 23, 2013. This SBIR Phase I award supports basic research and development activities at Celldex Therapeutics, a for-profit small...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Lineage Cell Therapeutics, Inc. for the development of high content screening of 3D cultured cancer cells. The contract has a ceiling value of $285,423 and is a definitive, firm fixed-price contract with a completion date of September 4, 2014. The contract is set aside for small businesses. No other subcontractors are mentioned in the provided information.
This is a $399,062 firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI) to Avoneaux Medical Institute, LLC for the development of spatial micro-purification technology. The contract was set aside for small businesses and is part of the NCI's broader SBIR program, which funds research and development in support of the NIH and CDC's mission needs. The original solicitation sought proposals on a range of cancer-related topics, including alternatives to cell...
This contract was awarded by the National Cancer Institute to Proteios Technology, Inc., a self-certified small disadvantaged business. The $455,000 firm-fixed-price contract is for a 1-year Small Business Innovation Research (SBIR) Phase I project focused on developing a new paradigm for autologous and allogeneic cell therapy manufacturing. The contract is part of the NCI's SBIR program, which aims to stimulate technological innovation and increase commercialization of federal research and...
This $399,987 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to Care Progress LLC, a small business limited liability company. The contract supports the development of cancer clinical trials recruitment and retention tools for participant engagement, as described in the original SBIR solicitation. The solicitation sought proposals for SBIR Phase I and Phase II contracts to conduct...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nvigen, Inc., a small disadvantaged business and woman-owned manufacturer. The contract is for the development of cell-free tumor DNA (ctDNA) diagnostic enabled by magnetic automation assays, under SBIR Topic 353. The contract has a firm fixed price of $275,261.00 and a completion date of August 18, 2017. The contract does not utilize a set-aside...